Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishikawa, Y.
Right arrow Articles by Fukushima, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishikawa, Y.
Right arrow Articles by Fukushima, M.
Clinical Cancer Research Vol. 5, 883-889, April 1999
© 1999 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Dihydropyrimidine Dehydrogenase Activity and Messenger RNA Level May Be Related to the Antitumor Effect of 5-Fluorouracil on Human Tumor Xenografts in Nude Mice

Yoichiro Ishikawa, Tetsuro Kubota1, Yoshihide Otani, Masahiko Watanabe, Tatsuo Teramoto, Koichiro Kumai, Masaki Kitajima, Teiji Takechi, Hiroyuki Okabe and Masakazu Fukushima

Department of Surgery, School of Medicine, Keio University, Tokyo 160-8582 [Y. I., T. K., Y. O., M. W., T. Te., K. K., M. K.]; and Cancer Research Laboratory, Taiho Pharmaceutical Co. Ltd., Saitama 357-8527 [T. Ta., H. O., M. F.], Japan

We investigated the correlation between tumor sensitivity to 5-fluorouracil (5-FU) and the enzymatic activity and mRNA levels of thymidylate synthetase (TS) and dihydropyrimidine dehydrogenase (DPD) using human tumor xenografts in nude mice. Three gastric carcinoma xenografts (SC-1-NU, St-4, and H-111), two colon carcinoma xenografts (Co-4 and Col-3-JCK), one pancreatic carcinoma xenograft (PAN-3-JCK), and one breast carcinoma xenograft (MX-1) were inoculated into nude mice. When the resultant tumors reached 100–300 mg, 5-FU was administered i.p. at a dose of 60 mg/kg in a schedule of three times every 4 days, and the antitumor activity of 5-FU was evaluated as the relative mean tumor weight in treated mice compared to control mice. Xenografts were also inoculated into untreated nude mice. When tumors weighed 200–300 mg, tumor tissues were resected for measurement of tumoral TS and DPD. TS and DPD activities were detected by the TS-binding assay and a radioenzymatic assay, respectively. mRNA levels were measured by semiquantitative reverse transcription-PCR, with glyceraldehyde-3-phosphate dehydrogenase coamplified as an internal standard. TS and DPD activities ranged from 84.7 to 775.5 fmol/mg protein and from not detectable to 79.7 pmol/min/mg protein, respectively. TS and DPD mRNA levels ranged from 0.51 to 9.90 and from not detectable to 0.93, respectively. The enzymatic activities of TS and DPD were correlated with observed mRNA levels. DPD levels were significantly correlated with 5-FU sensitivity, with high DPD activity and high DPD mRNA level resulting in low sensitivity to 5-FU. In contrast, no correlation between TS level and 5-FU sensitivity was observed. Tumoral DPD activity and DPD mRNA level may be useful indicators in predicting the antitumor activity of 5-FU.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
W. Ichikawa, H. Uetake, Y. Shirota, H. Yamada, N. Nishi, Z. Nihei, K. Sugihara, and R. Hirayama
Combination of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Gene Expressions in Primary Tumors as Predictive Parameters for the Efficacy of Fluoropyrimidine-based Chemotherapy for Metastatic Colorectal Cancer
Clin. Cancer Res., February 1, 2003; 9(2): 786 - 791.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
Y. Shirota, W. Ichikawa, H. Uetake, H. Yamada, Z. Nihei, and K. Sugihara
Intratumoral Dihydropyrimidine Dehydrogenase Messenger RNA Level Reflects Tumor Progression in Human Colorectal Cancer
Ann. Surg. Oncol., July 1, 2002; 9(6): 599 - 603.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M.-C. Etienne, M. Chazal, P. Laurent-Puig, N. Magne, C. Rosty, J.-L. Formento, M. Francoual, P. Formento, N. Renee, E. Chamorey, et al.
Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses
J. Clin. Oncol., June 15, 2002; 20(12): 2832 - 2843.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Tanaka-Nozaki, M. Onda, N. Tanaka, and S. Kato
Variations in 5-Fluorouracil Concentrations of Colorectal Tissues as Compared with Dihydropyrimidine Dehydrogenase (DPD) Enzyme Activities and DPD Messenger RNA Levels
Clin. Cancer Res., September 1, 2001; 7(9): 2783 - 2787.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. B. P. van Kuilenburg, E. W. Muller, J. Haasjes, R. Meinsma, L. Zoetekouw, H. R. Waterham, F. Baas, D. J. Richel, and A. H. van Gennip
Lethal Outcome of a Patient with a Complete Dihydropyrimidine Dehydrogenase (DPD) Deficiency after Administration of 5-Fluorouracil: Frequency of the Common IVS14+1G>A Mutation Causing DPD Deficiency
Clin. Cancer Res., May 1, 2001; 7(5): 1149 - 1153.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
J. L. Grem, K. D. Danenberg, K. Behan, A. Parr, L. Young, P. V. Danenberg, D. Nguyen, J. Drake, A. Monks, and C. J. Allegra
Thymidine Kinase, Thymidylate Synthase, and Dihydropyrimidine Dehydrogenase Profiles of Cell Lines of the National Cancer Institute's Anticancer Drug Screen
Clin. Cancer Res., April 1, 2001; 7(4): 999 - 1009.
[Abstract] [Full Text]


Home page
JCOHome page
R. Fujiwaki, K. Hata, K. Nakayama, M. Fukumoto, and K. Miyazaki
Gene Expression for Dihydropyrimidine Dehydrogenase and Thymidine Phosphorylase Influences Outcome in Epithelial Ovarian Cancer
J. Clin. Oncol., December 1, 2000; 18(23): 3946 - 3951.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. L. Grem, N. Harold, J. Shapiro, D.-Q. Bi, M. G. Quinn, S. Zentko, B. Keith, J. M. Hamilton, B. P. Monahan, S. Donavan, et al.
Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors
J. Clin. Oncol., December 1, 2000; 18(23): 3952 - 3963.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. B. P. van Kuilenburg, J. Haasjes, D. J. Richel, L. Zoetekouw, H. Van Lenthe, R. A. De Abreu, J. G. Maring, P. Vreken, and A. H. van Gennip
Clinical Implications of Dihydropyrimidine Dehydrogenase (DPD) Deficiency in Patients with Severe 5-Fluorouracil-associated Toxicity: Identification of New Mutations in the DPD Gene
Clin. Cancer Res., December 1, 2000; 6(12): 4705 - 4712.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
F. Tanaka, Y. Otake, T. Nakagawa, Y. Kawano, R. Miyahara, M. Li, K. Yanagihara, J. Nakayama, I. Fujimoto, K. Ikenaka, et al.
Expression of Polysialic Acid and STX, a Human Polysialyltransferase, Is Correlated with Tumor Progression in Non-Small Cell Lung Cancer
Cancer Res., June 1, 2000; 60(11): 3072 - 3080.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Cabelguenne, H. Blons, I. de Waziers, F. Carnot, A.-M. Houllier, T. Soussi, D. Brasnu, P. Beaune, O. Laccourreye, and P. Laurent-Puig
p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series
J. Clin. Oncol., April 7, 2000; 18(7): 1465 - 1473.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Uetake, W. Ichikawa, T. Takechi, M. Fukushima, Z. Nihei, and K. Sugihara
Relationship between Intratumoral Dihydropyrimidine Dehydrogenase Activity and Gene Expression in Human Colorectal Cancer
Clin. Cancer Res., October 1, 1999; 5(10): 2836 - 2839.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.